Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C

NCT00239252 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2014-08-26

No results posted yet for this study

Summary

Efficacy and safety is compared between interferon alfacon-1 alone and concomitant dosing of interferon alfacon-1 and ribavirin in hepatitis C patients.

Conditions

  • Hepatitis C

Interventions

DRUG

Interferon alfacon-1

Sponsors & Collaborators

  • Schering-Plough

    collaborator INDUSTRY
  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Clinical Development III · Astellas Pharm. Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Japan

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00239252 on ClinicalTrials.gov